1-tert-butyl-9-fluorenone | 166985-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 1-tert-butyl-9-fluorenone
• 英文别名: 1-Tert-butylfluoren-9-one
• CAS: 166985-47-3
• 化学式: C₁₇H₁₆O
• 分子量: 236.313
• InChiKey: RRSQCIQJUOTVGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-tert-butyl-9-fluorenone 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以52%的产率得到1-tert-butyl-9-fluorenol
  参考文献：
  名称：

  Chemistry of 1-Alkylfluorenylidenes. Steric Effects on Arylcarbene Reactivities

  摘要：

  9-Diazofluorenes (RDAF, 1) having a series of alkyl (R) groups from Me to tBu at the 1-position were prepared and decomposed to generate the corresponding fluorenylidenes (RFL, 2) under various conditions in order to examine steric effects on the reactivities of carbenes. Thus, in cyclohexane, singlet fluorenylidenes ((1)RFLs) gave 9-cyclohexylfluorenes while triplet states ((3)RFLs) underwent H abstraction to give 9-fluorenyl (RFLH(.)), which eventually led to fluorene (4, RFLH(2)) and 9,9'bifluorenyl (5), and the ratio of the triplet products to the singlet was increased as more bulky R groups were introduced at the 1-position. These results are interpreted in terms of the steric effects on singlet reactivity, which requires formation of two bonds simultaneously. Generation of tBuFL resulted in the almost exclusive formation of intramolecular reaction products which involved not only insertion of carbene into the delta-C-H bonds of the tert-butyl group but also insertion of the 1,5-biradical, followed by neophyl-type rearrangement. The results are understood as indicating that abstraction of the delta-H by (3)tBuFL gains over the concerted intramolecular C-H insertion in (1)tBuFL. Generation of 1-RFL (R = Et, iPr, tBu) in the gas phase at high temperature gave intramolecular reaction products both in singlet and in triplet states, but the ratio of the singlet to the triplet product increased in going from Et to iPr to tBu presumably due to the increased opportunities of (1)FL to be trapped by delta-C-H bonds. Spectroscopic studies using matrix isolation techniques as well as laser flash photolysis were also carried out to gain information on the intermediates.

  DOI：

  10.1021/ja00121a007
• 作为产物：
  描述：

  1-溴-2-叔丁基苯 在 盐酸 、 magnesium 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 反应 6.5h， 生成 1-tert-butyl-9-fluorenone
  参考文献：
  名称：

  Chemistry of 1-Alkylfluorenylidenes. Steric Effects on Arylcarbene Reactivities

  摘要：

  9-Diazofluorenes (RDAF, 1) having a series of alkyl (R) groups from Me to tBu at the 1-position were prepared and decomposed to generate the corresponding fluorenylidenes (RFL, 2) under various conditions in order to examine steric effects on the reactivities of carbenes. Thus, in cyclohexane, singlet fluorenylidenes ((1)RFLs) gave 9-cyclohexylfluorenes while triplet states ((3)RFLs) underwent H abstraction to give 9-fluorenyl (RFLH(.)), which eventually led to fluorene (4, RFLH(2)) and 9,9'bifluorenyl (5), and the ratio of the triplet products to the singlet was increased as more bulky R groups were introduced at the 1-position. These results are interpreted in terms of the steric effects on singlet reactivity, which requires formation of two bonds simultaneously. Generation of tBuFL resulted in the almost exclusive formation of intramolecular reaction products which involved not only insertion of carbene into the delta-C-H bonds of the tert-butyl group but also insertion of the 1,5-biradical, followed by neophyl-type rearrangement. The results are understood as indicating that abstraction of the delta-H by (3)tBuFL gains over the concerted intramolecular C-H insertion in (1)tBuFL. Generation of 1-RFL (R = Et, iPr, tBu) in the gas phase at high temperature gave intramolecular reaction products both in singlet and in triplet states, but the ratio of the singlet to the triplet product increased in going from Et to iPr to tBu presumably due to the increased opportunities of (1)FL to be trapped by delta-C-H bonds. Spectroscopic studies using matrix isolation techniques as well as laser flash photolysis were also carried out to gain information on the intermediates.

  DOI：

  10.1021/ja00121a007

文献信息

• WNT INHIBITORS FOR HUMAN STEM CELL DIFFERENTIATION
  申请人：Cashman John

  公开号：US20130177535A1

  公开（公告）日：2013-07-11

  Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II: or a pharmaceutically acceptable salt or solvate thereof, wherein A, X, Q, R 1 , R 2 , R 3 , R 4 are as described herein.

  提供了用于干细胞分化和治疗患有疾病的动物的方法和小分子化合物。可以使用的一类化合物的一个示例由式I和II表示： 或其药用可接受的盐或溶剂，其中A、X、Q、R1、R2、R3、R4如本文所述。
• CATHEPSIN S INHIBITORS
  申请人：Lin Chun-Cheng

  公开号：US20110166141A1

  公开（公告）日：2011-07-07

  Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.

  具有(I)、(II)、(III)或(IV)公式的卡特普西林S抑制剂，如规范所示。这些抑制剂可用于治疗癌症和自身免疫/炎症性疾病。
• Fucosidase inhibitors
  申请人：HORIZON ORPHAN LLC

  公开号：US10308607B2

  公开（公告）日：2019-06-04

  The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.

  本公开总体上涉及作为岩藻糖苷酶抑制剂的化合物，以及用本文公开的化合物治疗肿瘤或癌症，如肝脏疾病和肝脏肿瘤（如肝细胞癌）的方法和组合物。
• NISHIDA, AKIKO;SUMIDA, TSUYOSHI;KUGISAKI, RYUJI;, FUJISAKI SHIZUO;KAJIGAE+, YAMAGUTI DAJGAKU KOGAKUBU KEHNKYU XOKOKU, 40,(1989) N, S. 139-144
  作者：NISHIDA, AKIKO、SUMIDA, TSUYOSHI、KUGISAKI, RYUJI、, FUJISAKI SHIZUO、KAJIGAE+

  DOI：——

  日期：——
• FUCOSIDASE INHIBITORS
  申请人：RAPTOR PHARMACEUTICALS INC.

  公开号：US20170029376A1

  公开（公告）日：2017-02-02

  The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.